New Launch19 Nov 2024, 12:51 am
AstraZeneca Pharma India to Launch Breztri Aerosphere for COPD Treatment in January 2025
AI Summary
AstraZeneca Pharma India Limited has announced the launch of Breztri Aerosphere, a maintenance treatment for chronic obstructive pulmonary disease (COPD) in adult patients. The announcement comes after the receipt of Import and Market Permission in Form CT-20 from the Drugs Controller General of India for Budesonide Ph. Eur 160mcg+ Glycopyrronium Ph. Eur 7.2mcg+ Formoterol Fumarate Dihydrate Ph. Eur 5mcg inhalation preparations (Breztri Aerosphere) in December 2023.
Key Highlights
- AstraZeneca Pharma India Limited to launch Breztri Aerosphere in January 2025 in India
- Breztri Aerosphere is indicated for the maintenance treatment to relieve symptoms and prevent exacerbations in adult patients with COPD
- The announcement follows the receipt of Import and Market Permission in Form CT-20 from the Drugs Controller General of India for Breztri Aerosphere in December 2023